Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate: Mobility, musculoskeletal health and arthritis - ICS

University of Ottawa

$4,950.00

Improving Muscular Dystrophy Cell Therapy with Drug-Related Gene Knock-Down in Donor Cells

EF 2011-12

Résumé
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by the gradual weakening and deterioration of muscles in an individual. This problem is due to the absence of production of a specific protein, dystrophin. There is currently no therapy to treat DMD; however, one source of hope is that the injection of muscle stem cells, known as satellite cells, into the patients' muscles, would provide long-term improvement of muscle function, by providing the muscle tissue with stem cells that have a functional copy of the dystrophin gene. However, this therapy has been problematic because the injected cells differentiate prematurely, and do not establish the important pool of undifferentiated cells. The protein Six1 is known to promote the differentiation of satellite cells as muscle cells and inhibit the renewal of satellite cells. Therefore, it is proposed that temporarily reducing the activity of Six1 in satellite cells will allow for them to avoid premature differentiation. This reduction in Six1 activity is possible through the injection of small hairpin RNA (shRNA) molecules specific to the Six1 gene. These molecules are packaged in viruses which are then used to infect the donor satellite cells, and activated by exposure to the antibiotic tetracycline. The present research will aim to characterize the effects of the shRNA against Six1 (shSix1) in the repopulation of degenerated muscle by satellite cells in dystrophic mice. Donor cells will be prepared by infecting with viruses containing the proper shRNA and injected in tibialis anterior (TA) muscle of dystrophic mice. The state of the muscle will then be evaluated at different time points by examining protein content, and number of donor cells, satellite cells, and newly regenerated muscle cells. Theoretically, the donor cells treated with shSix1 should repopulate the muscle niche more effectively and therefore allow better regeneration of the muscle in the long term.
Programme
Undergraduate: Mobility, musculoskeletal health and arthritis - ICS
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
251801
Name
Antoun Alen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Undergraduate: Mobility, musculoskeletal health & arthritis - IMHA
Projecttitle
Improving Muscular Dystrophy Cell Therapy with Drug-Related Gene Knock-Down in Donor Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$4,950
Cihrequipment2
$0
Programname2
Undergraduate: Mobility, musculoskeletal health and arthritis - ICS
Keyworddelim
Cell Therapy; Drug-Regulated Gene Knock-Down; Duchenne Muscular Dystrophy; Immunostaining; Lentivirus; Satellite Cells; Shrna; Six1
Abstract
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by the gradual weakening and deterioration of muscles in an individual. This problem is due to the absence of production of a specific protein, dystrophin. There is currently no therapy to treat DMD; however, one source of hope is that the injection of muscle stem cells, known as satellite cells, into the patients' muscles, would provide long-term improvement of muscle function, by providing the muscle tissue with stem cells that have a functional copy of the dystrophin gene. However, this therapy has been problematic because the injected cells differentiate prematurely, and do not establish the important pool of undifferentiated cells. The protein Six1 is known to promote the differentiation of satellite cells as muscle cells and inhibit the renewal of satellite cells. Therefore, it is proposed that temporarily reducing the activity of Six1 in satellite cells will allow for them to avoid premature differentiation. This reduction in Six1 activity is possible through the injection of small hairpin RNA (shRNA) molecules specific to the Six1 gene. These molecules are packaged in viruses which are then used to infect the donor satellite cells, and activated by exposure to the antibiotic tetracycline. The present research will aim to characterize the effects of the shRNA against Six1 (shSix1) in the repopulation of degenerated muscle by satellite cells in dystrophic mice. Donor cells will be prepared by infecting with viruses containing the proper shRNA and injected in tibialis anterior (TA) muscle of dystrophic mice. The state of the muscle will then be evaluated at different time points by examining protein content, and number of donor cells, satellite cells, and newly regenerated muscle cells. Theoretically, the donor cells treated with shSix1 should repopulate the muscle niche more effectively and therefore allow better regeneration of the muscle in the long term.
Competitiondate
201201
Approvedterm2
0 yr 3 mths
Pinamesdelim
Antoun, Alen
Approvedterm
0 an 3 mois
Cihrcontribution2
~ $4,950~ $0~